News

Sirturo (bedaquiline) approved for conditional use in European Union to treat MDR-TB in adults

The European Medicines Agency (EMA) has recently approved Sirturo (bedaquiline) for conditional use in the European Union for adults suffering from pulmonary MDR-TB.

The press release from Multimedia News Release can be found at:

http://www.multivu.com/mnr/65014-sirturo-treatment-multi-drug-resistant-tuberculosis

Back in December 2012, the same drug was approved by the US Food and Drug Administration. The blog post highlighting that announcement can be found at:

http://dev-wgnd-blog.pantheonsite.io/bedaquiline-receives-accelerated-approval-from-the-fda-for-mdr-tb-rx/

More News
29 Nov 2018
On December 6, 2018, at 7AM EST, TREAT TB will host a capacity building webinar on community engagement in MDR-TB clinical trials. It will feature a presentation from Ezio Tavora dos Santos Filho, STREAM Community Engagement Coordinator from REDE-TB , followed by a question and answer session. The...
2 Oct 2018
The first ever U.N. General Assembly’s high-level meeting (UNHLM) on tuberculosis took place on Wednesday, September 26 in New York City. The U.N. delegation of countries agreed to ambitious targets including a commitment to finding 40 million undiagnosed cases of TB by the end of 2022 and...
18 Sep 2018
In an article written by Lucica Ditiu, Executive Director, Stop TB Partnership, and Jacqueline Huh, Head, Strategic Initiatives & Innovative Financing, Stop TB, the 'valleys of death' that hold back TB new tools innovation are discussed. These two valleys occur between new tool development and...